|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Phillips-Chavez C, Watson M, Coward J and
Schloss J: A systematic literature review assessing if genetic
biomarkers are predictors for platinum-based chemotherapy response
in ovarian cancer patients. Eur J Clin Pharmacol. 76:1059–1074.
2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Zhang R, Shi H, Ren F, Feng W, Cao Y, Li
G, Liu Z, Ji P and Zhang M: MicroRNA-338-3p suppresses ovarian
cancer cells growth and metastasis: Implication of Wnt/catenin beta
and MEK/ERK signaling pathways. J Exp Clin Cancer Res.
38(494)2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wen J, Zhao Z, Huang L, Wang L, Miao Y and
Wu J: IL-8 promotes cell migration through regulating EMT by
activating the Wnt/β-catenin pathway in ovarian cancer. J Cell Mol
Med. 24:1588–1598. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kan T, Wang W, Ip PP, Zhou S, Wong AS,
Wang X and Yang M: Single-cell EMT-related transcriptional analysis
revealed intra-cluster heterogeneity of tumor cell clusters in
epithelial ovarian cancer ascites. Oncogene. 39:4227–4240.
2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Wang S, Wang C, Li X, Hu Y, Gou R, Guo Q,
Nie X, Liu J, Zhu L and Lin B: Down-regulation of TRIB3 inhibits
the progression of ovarian cancer via MEK/ERK signaling pathway.
Cancer Cell Int. 20(418)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Liu J, Hu HB, Liu YM, Li FX, Zhang LP and
Liao ZM: LncRNA HOTTIP promotes the proliferation and invasion of
ovarian cancer cells by activating the MEK/ERK pathway. Mol Med
Rep. 22:3667–3676. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Wu PK, Becker A and Park JI: Growth
inhibitory signaling of the Raf/MEK/ERK pathway. Int J Mol Sci.
21(21)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Parker MI, Nikonova AS, Sun D and Golemis
EA: Proliferative signaling by ERBB proteins and RAF/MEK/ERK
effectors in polycystic kidney disease. Cell Signal.
67(109497)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Nayak A and Amrute-Nayak M: SUMO system -
a key regulator in sarcomere organization. FEBS J. 287:2176–2190.
2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Varejão N, Lascorz J, Li Y and Reverter D:
Molecular mechanisms in SUMO conjugation. Biochem Soc Trans.
48:123–135. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wan W, Zhang X, Huang C, Chen L, Yang X,
Bao K and Peng T: Monensin inhibits glioblastoma angiogenesis via
targeting multiple growth factor receptor signaling. Biochem
Biophys Res Commun. 530:479–484. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Gu J, Huang L and Zhang Y: Monensin
inhibits proliferation, migration, and promotes apoptosis of breast
cancer cells via downregulating UBA2. Drug Dev Res. 81:745–753.
2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Dayekh K, Johnson-Obaseki S, Corsten M,
Villeneuve PJ, Sekhon HS, Weberpals JI and Dimitroulakos J:
Monensin inhibits epidermal growth factor receptor trafficking and
activation: Synergistic cytotoxicity in combination with EGFR
inhibitors. Mol Cancer Ther. 13:2559–2571. 2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Markowska A, Kaysiewicz J, Markowska J and
Huczyński A: Doxycycline, salinomycin, monensin and ivermectin
repositioned as cancer drugs. Bioorg Med Chem Lett. 29:1549–1554.
2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Rajendran V, Ilamathi HS, Dutt S,
Lakshminarayana TS and Ghosh PC: Chemotherapeutic potential of
monensin as an anti-microbial agent. Curr Top Med Chem.
18:1976–1986. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Xin H, Li J, Zhang H, Li Y, Zeng S, Wang
Z, Zhang Z and Deng F: Monensin may inhibit melanoma by regulating
the selection between differentiation and stemness of melanoma stem
cells. PeerJ. 7(e7354)2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yusenko MV, Trentmann A, Andersson MK,
Ghani LA, Jakobs A, Arteaga Paz MF, Mikesch JH, Peter von Kries J,
Stenman G and Klempnauer KH: Monensin, a novel potent MYB
inhibitor, suppresses proliferation of acute myeloid leukemia and
adenoid cystic carcinoma cells. Cancer Lett. 479:61–70.
2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Vanneste M, Huang Q, Li M, Moose D, Zhao
L, Stamnes MA, Schultz M, Wu M and Henry MD: High content screening
identifies monensin as an EMT-selective cytotoxic compound. Sci
Rep. 9(1200)2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Hu M, Zhang Y, Li X, Cui P, Li J,
Brännström M, Shao LR and Billig H: Alterations of endometrial
epithelial-mesenchymal transition and MAPK signalling components in
women with PCOS are partially modulated by metformin in vitro. Mol
Hum Reprod. 26:312–326. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Xin L, Zhao R, Lei J, Song J, Yu L, Gao R,
Ha C, Ren Y, Liu X, Liu Y, et al: SND1 acts upstream of SLUG to
regulate the epithelial-mesenchymal transition (EMT) in SKOV3
cells. FASEB J. 33:3795–3806. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Sommariva M and Gagliano N: E-cadherin in
pancreatic ductal adenocarcinoma: A multifaceted actor during EMT.
Cells. 9(9)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Avtanski D, Garcia A, Caraballo B,
Thangeswaran P, Marin S, Bianco J, Lavi A and Poretsky L: Resistin
induces breast cancer cells epithelial to mesenchymal transition
(EMT) and stemness through both adenylyl cyclase-associated protein
1 (CAP1)-dependent and CAP1-independent mechanisms. Cytokine.
120:155–164. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wang K, Li T, Xu C, Ding Y, Li W and Ding
L: Claudin-7 downregulation induces metastasis and invasion in
colorectal cancer via the promotion of epithelial-mesenchymal
transition. Biochem Biophys Res Commun. 508:797–804.
2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Jansen NS and Vertegaal ACO: A chain of
events: Regulating target proteins by SUMO polymers. Trends Biochem
Sci. 46:113–123. 2021.PubMed/NCBI View Article : Google Scholar
|
